Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Open Lable, Single Arm, Trial to Determine Efficacy and Safety of Lenvatinib in Combination With Pembrolizumab for Platinum- Sensitive Recurrent Ovarian Cancer

NCT04519151 is registered in ClinicalTrials.gov with Sheba Medical Center as lead sponsor.

NCT NCT04519151
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04519151 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Open Lable, Single Arm, Trial to Determine Efficacy and Safety of Lenvatinib in Combination With Pembrolizumab for Platinum- Sensitive Recurrent Ovarian Cancer
Lead sponsor
Sheba Medical Center
Phase
Phase 2
Overall status
Recruiting
Start date
April 12, 2021
Completion date
November 30, 2029
Enrollment
24 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, ovarian epithelial, genital neoplasms, female, neoplasm of stomach, neoplasms, glandular and epithelial, ovarian diseases, ovarian epithelial tumor, ovarian neoplasms, urogenital neoplasms